S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SLRN ACELYRIN Inc

3.30

0.16 (5.10%)

03 Jan 2025 - Closed

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more ACELYRIN Charts.

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more ACELYRIN Charts.

ACELYRIN Inc News

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Friday 3 January 2025 (1 hour ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 11 December 2024 (3 weeks ago) • Edgar (US Regulatory)

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Wednesday 11 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Thursday 14 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Saturday 9 November 2024 (2 months ago) • Edgar (US Regulatory)

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
Thursday 7 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K/A - Current report: [Amend]
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
Wednesday 16 October 2024 (3 months ago) • GlobeNewswire Inc.

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Thursday 19 September 2024 (3 months ago) • GlobeNewswire Inc.

More ACELYRIN Inc News Articles

Woodside Petroleum

Westpac Banking

Commonwealth Bank Of Aus...

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions